HK Stock Market Move | APEX ACE HLDG (06036) rose over 7% with a mid-term profit attributable to shareholders of HK$134 million, penetrating high-demand fields such as new energy and servers.
Guangli Technology (06036) rose more than 7%. As of the time of this report, it is up 7.56%, priced at HKD 1.28, with a trading volume of HKD 4.9754 million.
APEX ACE HLDG (06036) rose over 7%. As of the time of writing, it increased by 7.56%, trading at HKD 1.28, with a transaction amount of HKD 4.9754 million.
In terms of news, recently, APEX ACE HLDG announced its interim results for the six months ending June 30, 2026. The group recorded revenue of HKD 4.973 billion, a year-on-year increase of 126.25%; profit attributable to company owners was HKD 134 million, a year-on-year increase of 1149.28%; and basic earnings per share were HKD 0.1271.
The announcement stated that the revenue growth was mainly due to: a significant increase in product prices, driving revenue growth for core products; timely grasping of market price trends to enhance the groups product procurement and supply capabilities; and accelerating optimization of the customer structure, enabling the group to penetrate high-demand fields such as new energy and servers, thereby achieving simultaneous increases in both volume and price.
Related Articles

HK Stock Market Move | JST GROUP (06687) rose over 7% during trading hours. JST GROUP officially announced its elevation to a top partner of Meta.

China Securities Co., Ltd.: The fresh snack sector is currently experiencing a surge in stores, and leading brands are expected to stand out in the competition.

Goldman Sachs: Cuts the target price of SINOPHARM (01099) to HKD 18.46, second quarter results meet expectations.
HK Stock Market Move | JST GROUP (06687) rose over 7% during trading hours. JST GROUP officially announced its elevation to a top partner of Meta.

China Securities Co., Ltd.: The fresh snack sector is currently experiencing a surge in stores, and leading brands are expected to stand out in the competition.

Goldman Sachs: Cuts the target price of SINOPHARM (01099) to HKD 18.46, second quarter results meet expectations.

RECOMMEND





